BioCentury | Dec 15, 2017
Company News

Allergan to acquire Repros

...to treat abnormal uterine bleeding in women with uterine fibroids. Repros' pipeline includes SPRM Proellex telapristone acetate...
...and enclomiphene citrate to treat secondary hypogonadism. FDA has placed a partial clinical hold on Proellex...
...Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Allergan plc (NYSE:AGN), Dublin, Ireland Business: Endocrine/Metabolic, Genitourinary Jennie Walters enclomiphene citrate Proellex Proellex-V Allergan...
BioCentury | Apr 13, 2017
Clinical News

Proellex telapristone acetate: Clinical hold ongoing

...Repros said FDA confirmed it will maintain its partial clinical hold on oral Proellex telapristone acetate while...
...mg Proellex, and again in 2012 to allow Repros to conduct additional trials of low-dose Proellex...
...BioCentury, June 14, 2010 ). Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex telapristone acetate (CDB-4124...
BioCentury | Sep 26, 2016
Clinical News

Proellex telapristone: Phase II data

...vs. 11% for placebo (p=0.0423). Repros said 70% of patients treated with Proellex became amenorrheic. Proellex...
...became amenorrheic. Proellex was generally well tolerated. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex...
...was generally well tolerated. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex telapristone ( CDB-4124...
BioCentury | Apr 25, 2016
Clinical News

Telapristone: Phase IIb data

...women with severe menstrual bleeding due to uterine fibroids showed that 6 and 12 mg Proellex...
...1 course of treatment vs. placebo (52% for combined Proellex arms vs. 0%, p<0.0011). Additionally, Proellex-treated...
...uterine fibroids. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Telapristone ( Vaginal Proellex , Proellex-V...
BioCentury | Mar 19, 2015
Targets & Mechanisms

Refertilizing endometriosis

...trouble in the clinic. In 2009, FDA put a full clinical hold on trials of Proellex...
...at doses of 25 and 50 mg in Phase III trials. Before the clinical hold, Proellex...
...enhancer in B cells 1 PPARγ - Peroxisome proliferation activated receptor γ Proellex telapristone ( CDB-4124...
BioCentury | Jan 26, 2015
Clinical News

Proellex-V telapristone: Phase IIb started

...Repros began a double-blind, placebo-controlled Phase IIb trial to evaluate 6 and 12 mg Proellex vaginal...
...an off-drug interval to allow for menses. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex-V...
BioCentury | Jan 26, 2015
Clinical News

Telapristone: Phase IIb started

...Repros began a double-blind, placebo-controlled Phase IIb trial to evaluate 6 and 12 mg oral Proellex...
...for menses. Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Telapristone ( Proellex ) ( CDB-4124...
BioCentury | Mar 31, 2014
Clinical News

Proellex telapristone regulatory update

...Repros said FDA provided guidance for the company's clinical program for low-dose oral Proellex telapristone to...
...Proellex with a partial hold so that Repros could evaluate up to 12 mg of Proellex...
...BioCentury, June 14, 2010). Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex telapristone ( CDB-4124...
BioCentury | Nov 11, 2013
Clinical News

Proellex telapristone regulatory update

...a clinical trial for oral Proellex and a Phase IIb trial for vaginal Proellex ( Proellex-V...
...trial evaluating low-dose Proellex in endometriosis (see BioCentury, Oct. 15, 2012). Before the clinical hold, Proellex...
...progesterone receptor modulator (SPRM). Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex telapristone ( CDB-4124...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

...reduces circulating systemic estrogen. Aromatase inhibition also reduces circulating estrogen levels. Repros Therapeutics Inc. 's Proellex...
Items per page:
1 - 10 of 92